Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fagan

Showing results (401-410 of 489) with videos related to

Pageof 49
Sort By:
Science Translational Medicine|June 14, 2023
Gut microbiome composition may be an indicator of preclinical Alzheimer's diseaseAura L Ferreiro, JooHee Choi, Jian Ryou, et al.
Nature Medicine|January 16, 2019
Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunctionDaniel A Nation, Melanie D Sweeney, Axel Montagne, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 14, 2023
Cross-sectional and longitudinal comparisons of biomarkers and cognition among asymptomatic middle-aged individuals with a parental history of either autosomal dominant or late-onset Alzheimer's diseaseChengjie Xiong, Lena M McCue, Virginia Buckles, et al.
Neurology|April 22, 2022
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament LightSuzanne E Schindler, Thomas K Karikari, Nicholas J Ashton, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 12, 2020
Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learningNicolai Franzmeier, Nikolaos Koutsouleris, Tammie Benzinger, et al.
Science Translational Medicine|March 7, 2014
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's diseaseAnne M Fagan, Chengjie Xiong, Mateusz S Jasielec, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 25, 2017
Preclinical Alzheimer's disease and longitudinal driving declineCatherine M Roe, Ganesh M Babulal, Denise M Head, et al.
Brain : a Journal of Neurology|December 17, 2021
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairmentAllan I Levey, Deqiang Qiu, Liping Zhao, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 26, 2011
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseReisa A Sperling, Paul S Aisen, Laurel A Beckett, et al.
JAMA Neurology|January 13, 2015
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional studyAdam S Fleisher, Kewei Chen, Yakeel T Quiroz, et al.
Pageof 49

Showing results (401-410 of 489) with videos related to

Sort By:
Pageof 49
Science Translational Medicine|June 14, 2023
Gut microbiome composition may be an indicator of preclinical Alzheimer's diseaseAura L Ferreiro, JooHee Choi, Jian Ryou, et al.
Nature Medicine|January 16, 2019
Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunctionDaniel A Nation, Melanie D Sweeney, Axel Montagne, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 14, 2023
Cross-sectional and longitudinal comparisons of biomarkers and cognition among asymptomatic middle-aged individuals with a parental history of either autosomal dominant or late-onset Alzheimer's diseaseChengjie Xiong, Lena M McCue, Virginia Buckles, et al.
Neurology|April 22, 2022
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament LightSuzanne E Schindler, Thomas K Karikari, Nicholas J Ashton, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 12, 2020
Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learningNicolai Franzmeier, Nikolaos Koutsouleris, Tammie Benzinger, et al.
Science Translational Medicine|March 7, 2014
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's diseaseAnne M Fagan, Chengjie Xiong, Mateusz S Jasielec, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 25, 2017
Preclinical Alzheimer's disease and longitudinal driving declineCatherine M Roe, Ganesh M Babulal, Denise M Head, et al.
Brain : a Journal of Neurology|December 17, 2021
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairmentAllan I Levey, Deqiang Qiu, Liping Zhao, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 26, 2011
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseReisa A Sperling, Paul S Aisen, Laurel A Beckett, et al.
JAMA Neurology|January 13, 2015
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional studyAdam S Fleisher, Kewei Chen, Yakeel T Quiroz, et al.
Pageof 49